Imunon says Phase 3 OVATION 3 ovarian cancer trial enrollment outpaces plan - IMNN News | RalliesImunon says Phase 3 OVATION 3 ovarian cancer trial enrollment outpaces plan
I
IMNN• Phase 3 ovarian cancer trial enrollment runs ahead of plan
- Imunon reported faster-than-planned enrollment in its Phase 3 OVATION 3 trial of IMNN-001 for newly diagnosed advanced ovarian cancer.
- Momentum was attributed to previously presented Phase 2 OVATION 2 survival evidence, viewed as supportive of the program’s risk-reward profile.
- The update cited a well-tolerated safety profile to date, with no major immune-related safety signals flagged in ongoing monitoring.
- Enrollment is projected to finish in Q2 2029, setting up two interim looks that could support an earlier BLA filing.
